CN113017718B

CN113017718B - Occlusion device

Info

Publication number: CN113017718B
Application number: CN201911361293.5A
Authority: CN
Inventors: 陈贤淼; 张翠茹
Original assignee: Lifetech Scientific Shenzhen Co Ltd
Current assignee: Lifetech Scientific Shenzhen Co Ltd
Priority date: 2019-12-25
Filing date: 2019-12-25
Publication date: 2023-04-18
Anticipated expiration: 2039-12-25
Also published as: CN113017718A

Abstract

The invention relates to a plugging device which comprises a plugging frame, wherein the plugging frame comprises a plurality of high polymer braided wires and a plurality of strands of high polymer fiber wires, the high polymer braided wires and the plurality of strands of high polymer fiber wires are mixed and braided to form the plugging frame, and each strand of high polymer fiber wire comprises a plurality of high polymer fiber wires; the high-molecular braided silk and the multi-strand high-molecular fiber thread have the characteristic of peak-shifting degradation. The occlusion device can reduce adverse effects on tissues and is beneficial to avoiding tissue inflammation.

Description

Occlusion device

Technical Field

The invention relates to the field of interventional medical instruments, in particular to a plugging instrument.

Background

This section provides background information related to the present disclosure only and is not necessarily prior art.

Percutaneous intervention therapy is a very rapidly developing means for treating diseases in recent years, and the application field of the therapy is also becoming wider and wider. Wherein, the device and the medicine can be placed at the heart, the arteriovenous vessels and other parts of the human body by adopting a transcatheter interventional therapy method. Wherein the apparatus can be a heart occluder, a vascular plug, a vascular filter, etc.

The transcatheter interventional cardiac occluder is one common instrument for transcatheter interventional treatment and may be used in treating congenital heart diseases, such as atrial septal defect, ventricular septal defect, unclosed arterial duct, unclosed foramen ovale, etc. in minimally invasive way.

The conventional cardiac occluder is usually made of shape memory alloy, the shape memory alloy is visible under medical imaging equipment such as a Digital Subtraction Angiography (DSA) and the like, and the implantation operation can be ensured to be smoothly performed under the condition that a developing marker structure is not additionally arranged. However, for the absorbable heart occluder made of polymer material, the polymer material itself is invisible or has poor visibility under medical imaging equipment such as DSA, and it is difficult to ensure smooth operation. In addition, although the absorbable heart occluder made of high polymer materials can be absorbed by the body, the concentrated release of excessive degradation products can easily cause tissue inflammation, and new adverse problems can be caused after occlusion is completed.

Disclosure of Invention

In view of the above, there is a need for an occlusion device that reduces adverse tissue effects and advantageously avoids tissue inflammation.

An occlusion instrument comprises an occlusion frame, wherein the occlusion frame comprises a plurality of polymer braided wires and a plurality of strands of polymer fiber wires, the polymer braided wires and the plurality of strands of polymer fiber wires are braided in a mixed manner to form the occlusion frame, and each strand of polymer fiber wire comprises a plurality of polymer fiber wires; the polymer braided wire and the multi-strand polymer fiber wire have peak staggering degradation characteristics.

In one embodiment, the plurality of polymer braided filaments are arranged in parallel to form a first-dimension filament, the plurality of polymer fiber threads are arranged in parallel to form a second-dimension filament, and the first-dimension filament and the second-dimension filament are interwoven to form the occlusion frame.

In one embodiment, a part of the plurality of polymer woven yarns is arranged in parallel to form a first dimension yarn, another part of the plurality of polymer woven yarns is arranged in parallel to the plurality of polymer fiber yarns to form a second dimension yarn, and the first dimension yarn and the second dimension yarn are interwoven to form the occlusion frame.

In one embodiment, the polymer braided filaments in the first dimension filaments and the polymer braided filaments in the second dimension filaments have peak-to-peak degradation characteristics; and/or the presence of a gas in the gas,

the plurality of polymer fiber threads in the second dimension silk threads have peak-shifting degradation characteristics.

In one embodiment, the filament diameter of the polymer woven filament in the first dimension filament thread is different from the filament diameter of the polymer woven filament in the second dimension filament thread; and/or the presence of a gas in the gas,

the second dimension silk thread comprises a plurality of strands of polymer fiber threads with different specifications.

In one embodiment, the ratio of the filament diameter of the polymer woven filament in the first dimension filament to the filament diameter of the polymer woven filament in the second dimension filament is in a range from 1 to 1.

In one embodiment, the ratio of the number of the polymer braided filaments in the first-dimension filaments to the sum of the number of the polymer braided filaments and the polymer fiber filaments in the second-dimension filaments ranges from 1 to 1.

In one embodiment, the size range of each strand of polymer fiber yarn is 50D/72F-100D/72F, and the diameter range of each polymer knitting silk is 0.1-0.5 mm.

In one embodiment, the material of at least one of the woven polymer filaments and the polymer fiber threads is a polymer visible under a medical imaging device, and the polymer visible under the medical imaging device comprises a degradable polymer and a visible substance grafted on a molecular chain of the degradable polymer.

In one embodiment, the polymer visible under the medical imaging device comprises the visible substance in a mass percentage range of 5% to 25%.

The plugging frame of the plugging device is formed by co-weaving of the plurality of polymer weaving wires and the plurality of polymer fiber wires, and compared with the polymer weaving wires, the polymer fiber wires are softer, so that the abrasion to tissues can be reduced, the clamping force of the plugging device is favorably reduced, and the adverse influence on the tissues is favorably reduced. Meanwhile, the polymer braided wire and the multi-strand polymer fiber wire have peak staggering degradation characteristics, and the degradation products are favorably prevented from being intensively released, so that tissue inflammation is avoided.

Drawings

FIG. 1 is a schematic structural view of an embodiment of an occlusion device;

FIG. 2 is a weave of an occluding frame of an occluding device of an embodiment;

figure 3 is a weave of an occluding frame of another embodiment occluding device;

FIG. 4 is a schematic structural diagram of a polymer fiber yarn according to an embodiment;

FIG. 5 is a schematic view of a fixing member and a polymer fiber thread according to an embodiment;

FIG. 6 is a schematic structural view of an embodiment of an occlusion device;

fig. 7 is a schematic view showing a state where a cross point is fixed by a fastener according to another embodiment.

Detailed Description

In order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with figures are described in detail below. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein, but rather should be construed as broadly as the present invention is capable of modification in various respects, all without departing from the spirit and scope of the present invention.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

Referring to FIG. 1, one embodiment of an occluding device 100 includes an occluding frame 20. Referring to fig. 2, the plugging frame 20 includes a plurality of polymer braided wires 202 and a plurality of polymer fiber wires 204, and the plurality of polymer braided wires 202 and the plurality of polymer fiber wires 204 are co-braided to form the plugging frame 20. The plugging frame 20 is of a net structure.

As shown in fig. 2, each strand of polymer fiber line 204 includes a plurality of polymer fiber lines 2042, and after the plurality of polymer fiber lines 2042 are gathered into one strand of polymer fiber line 204, the plurality of strands of polymer fiber lines 204 and the plurality of polymer knitting yarns 202 are mixed and knitted to form the plugging frame 20. The multiple polymer fiber threads 204 and the multiple polymer braided filaments 202 are braided in a mixed manner, so that the plugging frame 20 has sufficient mechanical properties to meet the implantation requirements, but compared with a single polymer braided filament 202, the single polymer fiber thread 2042 is relatively soft, the wear to tissues such as cardiac tissues and the like is relatively small, the clamping force of the plugging device 100 can be favorably reduced, and the adverse effect on the cardiac tissues can be reduced.

At least one of the polymer woven filaments 202 and the polymer fiber threads 204 is made of a polymer that is visible under the medical imaging device, so that the occlusion device 100 is visible under the medical imaging device without an additional development mark structure.

Moreover, compared with the mode of additionally arranging the limited and sporadically distributed developing mark structures, the material of at least one of the polymer knitting silk 202 and the polymer fiber line 204 of the blocking frame 20 is a polymer which can be seen under the medical imaging equipment, so that the blocking frame 20 can be seen not only locally but also in the whole outline under the medical imaging equipment, and the smooth operation is facilitated.

Conventional imaging marker structures are generally made of relatively dense metals, such as non-absorbable metals like gold, platinum, osmium, rhenium, etc., which remain in the body for a long time or even permanently after the absorbable occlusion frame 20 is degraded and absorbed by the body, thereby presenting a long-term clinical risk. When the polymer braided wire 202 and the polymer fiber line 204 are both biodegradable materials, the occlusion device 100 can be completely absorbed by the body, thereby avoiding the long-term clinical risk and being safe to use.

In one embodiment, the polymer visible under the medical imaging device includes a degradable polymer and a visible substance grafted to a molecular chain of the degradable polymer.

In one embodiment, the degradable polymer is at least one selected from the group consisting of levorotatory polylactic acid, racemic polylactic acid, polyglycolic acid, polylactic-glycolic acid copolymer, polyhydroxyalkanoate, polydioxanone, polycaprolactone, polygluconic acid, polyhydroxybutyric acid, polyanhydride, polyphosphoester, polyglycolic acid, and polydioxanone.

In one embodiment, the degradable polymer is a copolymer formed by copolymerizing at least two of monomers forming levorotatory polylactic acid, racemic polylactic acid, polyglycolic acid, polylactic acid-glycolic acid copolymer, polyhydroxyalkanoate, polydioxanone, polycaprolactone, polygluconic acid, polyhydroxybutyric acid, polyanhydride, polyphosphoester, polyglycolic acid, and polydioxanone.

In one embodiment, the visualization substance is an iodine-containing material.

In one embodiment, whether either or both of the polymer woven filaments 202 and the polymer fiber threads 204 are polymers visible under medical imaging equipment, the polymer woven filaments 202 and the polymer fiber threads 204 are made of biodegradable polymers, so that the occlusion device 100 can be completely degraded after the end of the service period without any residue, thereby avoiding a long-term clinical risk.

When the polymer knitting yarn 202 is a polymer visible in medical imaging equipment, the material of the degradable polymer in the polymer may be the same as or different from that of the polymer fiber yarn 204. When the polymer fiber line 204 is a polymer visible under the medical imaging device, the material of the degradable polymer in the polymer may be the same as or different from that of the polymer woven filament 202. Alternatively, when both are visibility materials, the degradable polymers in both may be the same or different.

In one embodiment, the polymer visible under the medical imaging device is at least one selected from the group consisting of iodinated polylactic acid (I-PLA), iodinated polycarbonate (I-PC), iodinated cellulose, iodinated polymethacrylate (I-PMMA), iodinated polyurethane (I-PU), and iodinated poly-epsilon-caprolactone (I-PCL). Partial groups on molecular chains of polylactic acid, polycarbonate, cellulose, polymethacrylate, polyurethane and poly epsilon-caprolactone are replaced by iodine (I), and the obtained polymer is visible under medical imaging equipment.

In one embodiment, the visible substance is present in the polymer visible under the medical imaging device in an amount ranging from 5% to 25% by weight, in order to meet the visual requirements and avoid excessive absorption of the visible substance (e.g., iodine) by the body, while providing the occluding frame 20 with sufficient mechanical properties.

In one embodiment, the single polymeric fiber thread 2042 is a medical absorbable suture thread. For example, the single polymer fiber line 2042 is a polyglycolide suture or a polylactic acid suture, or the like. The material of the polymer woven filament 202 is a polymer that can be seen under medical imaging equipment.

When the number of the polymer braided wires 202 is large and the number of the strands of the polymer fiber threads 204 is small, the mechanical property of the plugging frame 20 is good, but the effect of reducing the adverse effect on the tissues such as the heart tissue is weak. When the number of the polymer braided wires 202 is small and the number of the strands of the polymer fiber yarns 204 is large, the plugging frame 20 is soft, but has relatively weak mechanical properties and is easy to fall off from the plugging portion. Therefore, in one embodiment, the ratio of the number of the polymer knitting yarns 202 to the number of the polymer fiber yarns 204 is in the range of 2.

In one embodiment, each polymer fiber yarn 204 has a gauge of 50D/18F to 600D/144F to achieve both mechanical properties and flexibility. The 50D/18F means that each of the polymer fiber threads 204 includes 18 polymer fiber threads 2042, and the total mass of the 18 polymer fiber threads 2042 is 50 denier (D). 600D/144F have the same meaning and will not be described further herein.

In one embodiment, each polymer fiber strand 204 has a gauge in the range of 30D/72F to 100D/72F.

In one embodiment, the specification range of each polymer fiber yarn 204 is 50D/72F-100D/72F, and the diameter range of each polymer knitting yarn 202 is 0.1-0.5 mm, so as to satisfy the requirements of mechanical property and flexibility, so that the occlusion device 100 has weak tissue clamping and pressing, and weak tissue abrasion, but does not fall off from the defect.

In one embodiment, the polymer fiber yarn 204 has a size range of 50D/72F to 100D/72F, the filament diameter range of each polymer knitting filament 202 is 0.1 to 0.5 mm, the sum of the number of the polymer knitting filaments 202 and the number of the polymer fiber yarn 204 is 36 to 72, and the ratio of the number of the polymer knitting filaments 202 to the number of the polymer fiber yarn 204 is 1 to 1.

Further, in one embodiment, the ratio of the number of the polymer knitting yarns 202 to the number of strands of the polymer fiber yarns 204 ranges from 1. Compared with each high polymer knitting yarn 202, the volume of each high polymer fiber yarn 204 is fluffy, so that the blood adsorption is facilitated, the plugging is accelerated, and the plugging effect is improved. Therefore, the plugging device 100 woven in the above manner can absorb blood rapidly due to each strand of polymer fiber yarn 204, and the absorbed blood can form thrombus rapidly on each strand of polymer fiber yarn 204, so as to gradually form a more compact structure, thereby achieving complete plugging rapidly while taking mechanical properties, flexibility requirements and transportation performance into consideration. Thus, the occluding device 100 may omit the flow-blocking membrane. The flow-resistant film is omitted, the sewing procedure of the flow-resistant film is avoided, and the production efficiency is improved. In addition, the flow-blocking membrane is omitted, and the radial size of the occlusion device 100 after stretching can be significantly reduced, so that the conveying flexibility of the occlusion device 100 is significantly improved, and the delivery of a conveying sheath with a small diameter and the smooth passing of a curved blood vessel path are facilitated.

In one embodiment, the single polymer fiber thread 2042 degrades in a physiological fluid environment or a simulated physiological fluid environment earlier than the single polymer woven filament 202. Compared with the yarn diameter of a single polymer knitting yarn 202, the yarn diameter of the single polymer fiber yarn 2042 is much smaller, and on the basis that the degradation rate difference caused by the difference of the materials is smaller or no difference, the degradation rate of the single polymer fiber yarn 2042 is greater than that of the single polymer knitting yarn 202. Therefore, the polymer braided wire 202 and the polymer fiber wire 204 have the peak-staggered degradation characteristic, so that the condition that degradation products are intensively released can be avoided, tissue inflammation is avoided, and the use is safe.

The physiological fluid environment is a biological fluid environment such as a blood environment or a tissue fluid environment. The environment simulating physiological body fluid is physiological saline, DMEM solution, SBF solution, hanks solution, PBS solution and the like.

In one embodiment, the specification range of each strand of polymer fiber yarn 204 is 50D/72F-80D/72F, and the ratio of the number of polymer woven filaments 202 to the number of strands of polymer fiber yarn 204 is 1. Moreover, each strand of polymer fiber thread 204 contains at least two types of polymer fiber threads 2042, so that the at least two types of polymer fiber threads 2042 and the polymer braided wires 202 form three-level gradient peak-staggered degradation, the concentrated release of degradation products can be further avoided, and the tissue inflammation is avoided. Alternatively, the polymer woven filament 202 is a polymer woven filament of at least two specifications (for example, different filament diameters, or different degradation characteristics of materials), so that the polymer woven filament 202 and the polymer fiber 204 of the at least two specifications form three-level gradient peak-shifting degradation.

In one embodiment, one of the plurality of polymer braided filaments 202 and the plurality of polymer fiber threads 204 is used as a first dimension filament (e.g., a longitude filament) and the other is used as a second dimension filament (e.g., a latitude filament), and after the plurality of first dimension filaments are arranged in parallel and the plurality of second dimension filaments are arranged in parallel, the occlusion frame 20 is formed by one-over-one and up-down interlacing (as shown in fig. 2).

In one embodiment, the plurality of polymer knitting yarns 202 are formed as first-dimension yarns, the mixed yarn of the plurality of polymer knitting yarns 202 and the plurality of polymer fiber yarns 204 is formed as a second-dimension yarn, and the polymer knitting yarns 202 and the polymer fiber yarns 204 are alternately arranged in the mixed yarn of the plurality of polymer knitting yarns 202 and the plurality of polymer fiber yarns 204, as shown in fig. 3. The ratio of the total number of the first-dimension filaments to the total number of the mixed filaments (the sum of the number of the polymer knitting filaments 202 and the number of strands of the polymer fiber yarns 204 in the second-dimension filaments) is in a range of 1 to 1. Also, the polymer fiber thread 204 is a polymer that is visible under the medical imaging device. So set up, when taking into account mechanical properties, compliance requirement and blood adsorptivity, in shutoff frame 20, the visible polymer still comparatively evenly disperses under the medical imaging equipment, can instruct the profile structure of shutoff frame 20, but the use amount of the visible polymer is less under the medical imaging equipment to avoid too much visible material being absorbed by the organism.

In one embodiment, the plurality of polymer knitting yarns 202 are formed as first-dimension yarns, the mixed yarn of the plurality of polymer knitting yarns 202 and the plurality of polymer fiber yarns 204 is formed as a second-dimension yarn, and the polymer knitting yarns 202 and the polymer fiber yarns 204 are alternately arranged in the mixed yarn of the plurality of polymer knitting yarns 202 and the plurality of polymer fiber yarns 204. Further, the high-molecular braided filaments 202 in the mixed yarn and the high-molecular braided filaments 202 in the first-dimension yarn have peak-off degradation characteristics. According to the arrangement, mechanical property, softness requirement and blood adsorbability are considered, and meanwhile, the two polymer woven filaments 202 and the polymer fiber yarns 204 with the peak staggering degradation characteristic have the three-level gradient degradation characteristic, so that three-level peak staggering degradation is formed, and inflammatory reaction is avoided.

In one embodiment, the polymeric braided filaments 202 in the second dimension filaments (mixed filaments) and the polymeric braided filaments 202 in the first dimension filaments are the same material but have different filament diameters, such that the two polymeric braided filaments 202 in the plugging frame 20 have peak-to-peak degradation characteristics. Further, in an embodiment, the filament diameter of the polymer braided filament 202 in the first dimension filament is smaller than the filament diameter of the polymer braided filament 202 in the mixed filament, which facilitates the peak-shifting degradation and simultaneously helps to balance the mechanical properties of the first dimension filament and the second dimension filament, so that the occlusion device 100 is more reliably fixed to the defect site and has less abrasion to the tissue.

Further, in one embodiment, the ratio of the filament diameter of the polymer woven filament 202 in the first dimension filament to the filament diameter of the polymer woven filament 202 in the mixed filament is in the range of 1. The ratio range of the number of the macromolecular braided wires in the first-dimension silk threads to the sum of the number of the macromolecular braided wires 202 in the mixed silk threads and the number of the strands of the macromolecular fiber threads 204 is 1-1, so that the mechanical property, the flexibility requirement and the blood adsorbability are considered, and the peak-shifting degradation is realized.

In one embodiment, the filament diameters of the polymer braided filaments 202 in the mixed filament and the polymer braided filaments 202 in the first dimension filament are the same, but the materials are different, and the two different materials have peak-to-peak degradation characteristics to achieve peak-to-peak degradation.

It should be noted that the degradation of the polymer is a non-uniform degradation, and the mass retention of the polymer decreases drastically during a certain period of time, which is called the degradation spike phase. The peak-offset degradation refers to different time periods in which peak stages of degradation occur for different polymers. In the present application, it is defined that when the mass retention of the polymer (percentage of the remaining mass of the polymer to the initial mass) varies by more than 5% over a certain period of time, then this period of time is called the degradation peak phase.

In one embodiment, no matter how the plurality of polymer braided filaments 202 and the plurality of polymer fiber threads 204 are braided to form the occluding frame 20, each polymer fiber thread 204 has a plurality of polymer fiber threads 2042 that are gathered together, no connection, such as no bonding, between any two polymer fiber threads 2042, no fixing structure for connecting the two polymer fiber threads 2042, and the like (except for the sealing heads at the two ends of the occluding device 100, if any), as shown in fig. 4. In the plugging frame 20, the plurality of polymer fiber yarns 204 and the plurality of polymer braided wires 202 are overlapped up and down, and simply contact with each other, and no fixed connection is formed at the intersection. The polymer fiber lines 204 with the intersection points and the polymer knitting yarns 202 can slide relatively, and any polymer fiber line 2042 in each polymer fiber line 204 is restrained less by the arrangement mode, so that the volume of each polymer fiber line 204 is fluffy, blood can be adsorbed, thrombus can be formed quickly, and the plugging speed is increased.

In one embodiment, referring to fig. 5, each strand of polymer fiber yarn 204 is tied with at least one fastener 206 and then braided. Fig. 5 shows the fastener 206 in an unstrained state. The plugging frame 20 of this embodiment has relatively high grid stability, and each strand of polymer fiber 204 is fastened by at least one fixing member 206, so that the occurrence of undesirable phenomena such as thread hanging during the conveying process can be reduced, and the smoothness of the operation can be improved.

In one embodiment, referring again to fig. 1, the plugging frame 20 includes a first plugging unit 22, a second plugging unit 24 and a waist 26. The two ends of the waist 26 are respectively connected with the first plugging unit 22 and the second plugging unit 24 to form a two-disc and one-waist structure with two large ends and a small middle. The first plugging unit 22, the second plugging unit 24 and the waist portion 26 are of an integral structure. Each strand of polymer fiber yarn 204 is bound by three fixing members 206 (as shown in fig. 5) and then is co-woven with the polymer braided yarn 202 to form the occlusion frame 20, wherein one fixing member 206 is located in the first occlusion unit 22, one fixing member 206 is located in the second occlusion unit 204, and the other fixing member 206 is located in the waist portion 26, so that the stability of the occlusion frame 20 is improved, and meanwhile, the influence of the excessive rigidity of the whole occlusion device 100 on the conveying performance is avoided, and the excessive fixing members 206 are prevented from binding each strand of polymer fiber yarn 204, so that each strand of polymer fiber yarn 204 can still keep a relatively fluffy state, and the complete occlusion is realized relatively quickly.

It should be noted that the fastener 206 may be a metal fastener, such as a flexible wire. The anchors 206 may also be anchors formed of other flexible materials, such as surgical sutures. The securing member 206 is made of a bioabsorbable material so that the occluding device 100 can be completely absorbed by the body.

In one embodiment, referring to fig. 6, the first plugging unit 22 includes a first distal disk surface 222, a first proximal disk surface 224 and a first ridge 226 connecting the first distal disk surface 222 and the first proximal disk surface 224. The second packing element 24 includes a second distal disk face 242, a second proximal disk face 244, and a second ridge 246 connecting the second distal disk face 242 and the second proximal disk face 244. The plurality of fixing members 206 are disposed on the first plugging unit 22, the second plugging unit 24, and the waist portion 26 in a dispersed manner. The plurality of fasteners 206 on the first occluding unit 22 are located at the intersections of the first ridges 226. The plurality of fasteners 206 on the second occluding unit 24 are located at the intersection of the second ridges 246. The plurality of fastening members 206 on the lumbar section 26 are arranged along the circumferential direction of the lumbar section 26, and the plurality of fastening members 206 on the lumbar section 26 are located on the same plane.

In one embodiment, the fastener 206 is omitted, i.e., each strand of polymer fiber yarn 204 is not tied down with the fastener 206 prior to knitting. Referring to fig. 7, the plugging frame 20 further includes a fastener 208, and the fastener 208 is used to fix the intersection point of each polymer fiber line 204 and the polymer braided wire 202, so that at the intersection point, each polymer fiber line 204 and the polymer braided wire 202 are fixedly connected to improve the stability of the plugging frame 20.

In order to avoid the difficulty in transportation due to the excessively increased rigidity of the plugging frame 20, and to maintain the fluffy state of each polymer fiber yarn 204 as much as possible, the number of the fastening members 208 is not excessively large. However, when the number of the fasteners 208 is too small, it is difficult to achieve the technical effect of increasing stability. Thus, in one embodiment, the number of intersections secured by the fasteners 208 comprises 25% to 50% of the total number of intersections of the occluding frame 20 to provide a compromise between mesh stability, transport compliance, and blood adherence.

In one embodiment, a plurality of fasteners 208 are disposed discretely on the first occluding unit 22, the second occluding unit 24, and the waist 26. Also, the plurality of fasteners 208 on the first plugging cell 22 are located at the intersection of the first ridges 226. The plurality of fasteners 208 on the second plugging cell 24 are located at the intersection of the second ridges 246. The plurality of fasteners 208 on the waist 26 are disposed circumferentially of the waist 26, and the plurality of fasteners 208 on the waist 26 are located on the same plane.

After the occlusion device 100 is implanted into the defect site, the first occlusion unit 22 and the second occlusion unit 24 of the occlusion device 100 are directly impacted by blood flow, and the plurality of fixing members 206 or the plurality of fastening members 208 are positioned on the first ridge 226 and the second ridge 246, so that the stability is improved, and at the same time, excessive binding of each strand of polymer fiber yarn 204 positioned on the first distal disc surface 222 and the first proximal disc surface 224, and the second distal disc surface 242 and the second proximal disc surface 244 is avoided, so that the fluffy state of the polymer fiber yarn is kept to the maximum extent, a compact structure is formed, and complete occlusion is realized as soon as possible. The waist 26 is located at the hole of the defect, and a plurality of fasteners 206 or a plurality of fasteners 208 are disposed along the circumference of the waist 26 to improve the supporting force of the waist 26 and to facilitate preventing the plugging device 100 from being displaced under the impact of blood flow.

The blocking instrument 100 has good visibility and can reduce adverse effects on tissues such as heart tissue. And the grid stability is better, the plugging effect is better, and the conveying flexibility is better.

It should be noted that the occlusion device 100 may be a heart occluder, a blood vessel occluder (e.g. a blood vessel plug), or the like.

The following is further illustrated by specific examples.

Example 1

An occlusion device comprises an occlusion frame, wherein the occlusion frame is formed by weaving a group of 18 parallelly arranged iodinated polylactic acid silk threads with the silk diameter of 0.40mm as longitude silk threads and a group of 18 parallelly arranged polylactic acid fiber threads as latitude silk threads in a one-to-one and up-and-down staggered manner. In the iodinated polylactic acid thread, the mass percent of iodine is 15%. The specification of each polylactic acid fiber wire is 50D/72F.

The occlusion device of example 1 was implanted in an eight-horse pig at a ventricular septal location, and during implantation, under DSA equipment, the occlusion device could be clearly identified. In two follow-up visits of 1 month and 3 months after implantation, no adverse phenomena such as conduction block and the like are found. After being implanted for 1 year, pathological section analysis is carried out on the plugging device and peripheral tissues, and no obvious inflammation or foreign body reaction exists.

Example 2

An occlusion device comprises an occlusion frame, wherein the occlusion frame is formed by weaving a group of 18 polylactic acid silk threads with the silk diameter of 0.30mm in parallel as longitude silk threads and a group of 36 iodinated polylactic acid fiber threads with the silk diameter of 0.30mm in parallel as latitude silk threads in a one-to-one and up-and-down staggered manner. In the iodinated polylactic acid thread, the mass percent of iodine is 11%. The specification of each polylactic acid fiber wire is 80D/72F.

The occlusion device of example 2 was implanted in an eight-horse pig at the ventricular septal site, and during implantation, under DSA equipment, the occlusion device could be clearly identified. In two follow-up visits of 1 month and 3 months after implantation, no adverse phenomena such as conduction block and the like are found. After being implanted for 1 year, the plugging device and peripheral tissues are analyzed by pathological sections, and obvious inflammation and foreign body reaction do not exist.

Example 3

An occlusion apparatus comprises an occlusion frame, wherein the occlusion frame is formed by a group of 18 parallel poly epsilon-caprolactone silk threads with the silk diameter of 0.20mm serving as longitude silk threads and a group of parallel mixed silk threads serving as latitude silk threads, the mixed silk threads comprise poly epsilon-caprolactone silk threads and iodinated poly epsilon-caprolactone fiber threads which are alternately arranged and arranged in parallel, the poly epsilon-caprolactone silk threads are 18 and the iodinated poly epsilon-caprolactone fiber threads are 18 strands, and the occlusion frame is formed by one-pressing one-up-down staggered weaving. In the iodinated polylactic acid thread, the mass percent of iodine is 10%. In the mixed silk threads, the specification of each iodinated poly-epsilon-caprolactone fiber thread is 30D/72F, and the silk diameter of the poly-epsilon-caprolactone silk thread is 0.40mm.

And soaking the poly epsilon-caprolactone silk threads (0.20 mm and 0.40 mm) and the iodinated poly epsilon-caprolactone fiber threads (30D/72F, and fastening by using a non-degradable fixing piece) of the two specifications in a PBS (phosphate buffer solution) at 37 ℃ for in-vitro degradation test, weighing the poly epsilon-caprolactone silk threads and the iodinated poly epsilon-caprolactone fiber threads of the two specifications every month, and drawing a trend curve of the change of mass retention rate along with time, wherein the time periods of degradation peak stages of the poly epsilon-caprolactone silk threads and the iodinated poly epsilon-caprolactone fiber threads of the two specifications are different.

The occlusion device of example 3 was implanted in an eight-horse pig at the ventricular septal site, and during implantation, under DSA equipment, the occlusion device could be clearly identified. In two follow-up visits of 1 month and 3 months after implantation, no adverse phenomena such as conduction block and the like are found. After being implanted for 1 year, pathological section analysis is carried out on the plugging device and peripheral tissues, and no obvious inflammation or foreign body reaction exists.

Example 4

An occlusion device comprises an occlusion frame, wherein the occlusion frame is formed by weaving a group of 18 polylactic acid silk threads with the silk diameter of 0.20mm in parallel as longitude silk threads and a group of 36 iodinated polylactic acid fiber threads with the silk diameter of 0.20mm in parallel as latitude silk threads in a one-to-one and up-and-down staggered manner. In the iodinated polylactic acid silk thread, the mass percent of iodine is 11%. The specification of each polylactic acid fiber wire is 100D/72F. Each strand of iodinated polylactic acid fiber thread is fastened by using 3 polylactic acid fiber threads as 3 fixing pieces respectively. Wherein, 3 fixed parts on each strand of classical polylactic acid fiber line are respectively positioned at the first plugging unit, the second plugging unit and the waist of the plugging frame.

The occlusion device of example 4 was implanted in an eight-horse pig at the ventricular septal site, and during implantation, under DSA equipment, the occlusion device could be clearly identified. In two follow-up visits of 1 month and 3 months after implantation, no adverse phenomena such as conduction block and the like are found. After being implanted for 1 year, the plugging device and peripheral tissues are analyzed by pathological sections, and obvious inflammation and foreign body reaction do not exist.

Example 5

An occlusion apparatus comprises an occlusion frame, wherein the occlusion frame is formed by weaving a group of 36 parallel poly epsilon-caprolactone silk threads with the silk diameter of 0.10mm as longitude silk threads and a group of parallel mixed silk threads as latitude silk threads, the mixed silk threads comprise poly epsilon-caprolactone silk threads and iodinated poly epsilon-caprolactone fiber threads which are alternately arranged and arranged in parallel, wherein the poly epsilon-caprolactone silk threads are 18 and the iodinated poly epsilon-caprolactone fiber threads are 36 strands in a one-to-one and up-and-down staggered manner. In the iodinated polylactic acid thread, the mass percent of iodine is 25%. In the mixed silk threads, the specification of each iodinated poly-epsilon-caprolactone fiber thread is 200D/72F, and the silk diameter of the poly-epsilon-caprolactone silk thread is 0.30mm. The blocking frame comprises a plurality of fasteners for fixing the crossing points of the blocking frame, and the fasteners are made of poly epsilon-caprolactone fiber threads. The sealing frame comprises a first ridge part, a second ridge part and a waist part, wherein a plurality of fasteners are arranged on the first ridge part, the second ridge part and the waist part of the sealing frame, and the fasteners positioned on the waist part are arranged along the circumferential direction of the waist part and positioned on the same plane. The number of intersections secured by the fasteners accounts for 25% of the total number of intersections of the plugging frame.

And soaking the poly epsilon-caprolactone silk threads (0.10 mm and 0.30 mm) and the iodinated poly epsilon-caprolactone fiber threads (30D/72F, and fastening by using a non-degradable fixing piece) of the two specifications in a PBS (phosphate buffer solution) at 37 ℃ for in-vitro degradation test, weighing the poly epsilon-caprolactone silk threads and the iodinated poly epsilon-caprolactone fiber threads of the two specifications every month, and drawing a trend curve of the change of mass retention rate along with time, wherein the time periods of degradation peak stages of the poly epsilon-caprolactone silk threads and the iodinated poly epsilon-caprolactone fiber threads of the two specifications are different.

The occluding device of example 5 was implanted in an eight horse pig at the ventricular septal site, and during implantation, under DSA equipment, the occluding device could be clearly identified. In two follow-up visits of 1 month and 3 months after implantation, no adverse phenomena such as conduction block and the like are found. After being implanted for 1 year, the plugging device and peripheral tissues are analyzed by pathological sections, and obvious inflammation and foreign body reaction do not exist.

Example 6

An occlusion device comprises an occlusion frame, wherein the occlusion frame is formed by weaving a group of 18 iodinated polylactic acid silk threads with the silk diameter of 0.50mm, which are arranged in parallel, as longitude silk threads and a group of 54 polylactic acid fiber threads, which are arranged in parallel, as latitude silk threads in a one-to-one and up-and-down staggered manner. In the iodinated polylactic acid thread, the mass percent of iodine is 15%. The specification of each polylactic acid fiber wire is 30D/72F. The blocking frame comprises a plurality of fasteners for fixing the crossing points of the blocking frame, and the fasteners are made of poly epsilon-caprolactone fiber threads. The sealing frame comprises a first ridge part, a second ridge part and a waist part, wherein a plurality of fasteners are arranged on the first ridge part, the second ridge part and the waist part of the sealing frame, and the fasteners positioned on the waist part are arranged along the circumferential direction of the waist part and positioned on the same plane. The number of intersections secured by the fasteners accounts for 50% of the total number of intersections of the plugging frame.

The occluding device of example 6 was implanted in an eight horse pig at the ventricular septal site, and during implantation, under DSA equipment, the occluding device could be clearly identified. In two follow-up visits of 1 month and 3 months after implantation, no adverse phenomena such as conduction block and the like are found. After being implanted for 1 year, the plugging device and peripheral tissues are analyzed by pathological sections, and obvious inflammation and foreign body reaction do not exist.

Example 7

An occlusion device comprises an occlusion frame, wherein the occlusion frame is formed by weaving a group of 72 parallelly arranged iodinated polylactic acid silk threads with the silk diameter of 0.30mm as longitude silk threads and a group of 36 parallelly arranged polylactic acid fiber threads as latitude silk threads in a one-to-one and up-and-down staggered manner. In the iodinated polylactic acid thread, the mass percent of iodine is 15%. The polylactic acid fiber yarns have two specifications, namely 30D/72F and 60D/72F, and the ratio of the number of strands of the polylactic acid fiber yarns with different specifications is 1. The blocking frame comprises a plurality of fasteners for fixing the crossing points of the blocking frame, and the fasteners are made of poly epsilon-caprolactone fiber threads. The sealing frame comprises a first ridge part, a second ridge part and a waist part, wherein a plurality of fasteners are arranged on the first ridge part, the second ridge part and the waist part of the sealing frame, and the fasteners positioned on the waist part are arranged along the circumferential direction of the waist part and positioned on the same plane. The number of intersections secured by the fasteners accounts for 30% of the total number of intersections of the plugging frame.

The occlusion device of example 7 was implanted in an eight-horse pig at a ventricular septal location, during which the occlusion device could be clearly identified under DSA equipment. In two follow-up visits of 1 month and 3 months after implantation, no adverse phenomena such as conduction block and the like are found. After being implanted for 1 year, the plugging device and peripheral tissues are analyzed by pathological sections, and obvious inflammation and foreign body reaction do not exist.

Example 8

A plugging device comprises a plugging frame, wherein the plugging frame is formed by using a group of 18 polylactic acid silk threads with the silk diameter of 0.10mm and arranged in parallel as longitude silk threads and a group of mixed silk threads with the silk diameter of 0.10mm and arranged in parallel as latitude silk threads, the mixed silk threads comprise polylactic acid silk threads and polylactic acid fiber threads which are alternately arranged and arranged in parallel, the polylactic acid silk threads are 18 strands, and the polylactic acid silk threads and the polylactic acid fiber threads are woven in a one-pressing one-up and one-down staggered mode to form the plugging frame. In the mixed silk threads, the specification of each polylactic acid fiber thread is 40D/72F, and the silk diameter of the polylactic acid silk thread is 0.4mm. The plugging frame comprises a plurality of fasteners for fixing the crossing points of the plugging frame, and the material of the fasteners is polylactic acid fiber thread. The plurality of fasteners are arranged on the first ridge portion, the second ridge portion and the waist portion of the plugging frame, and the plurality of fasteners located on the waist portion are arranged along the circumferential direction of the waist portion and located on the same plane. The number of intersections secured by the fasteners accounts for 35% of the total number of intersections of the occluding frame.

The polylactic acid silk thread and the polylactic acid fiber thread (40D/72F, fastened by a non-degradable fixing piece) are soaked in PBS buffer solution at 37 ℃ for in-vitro degradation test, the polylactic acid silk thread and the polylactic acid fiber thread are weighed every month, and a trend curve of the mass retention rate changing along with time is drawn, wherein the time periods of degradation peak stages of the polylactic acid silk thread and the polylactic acid fiber thread are different.

The occlusion device of example 8 was implanted in an eight-horse pig at the ventricular septal site, and during implantation, under DSA equipment, the occlusion device could be clearly identified. In two follow-up visits of 1 month and 3 months after implantation, no adverse phenomena such as conduction block and the like are found. After being implanted for 1 year, the plugging device and peripheral tissues are analyzed by pathological sections, and obvious inflammation and foreign body reaction do not exist.

Example 9

A plugging device comprises a plugging frame, wherein the plugging frame is formed by using a group of 18 polylactic acid silk threads with the silk diameter of 0.20mm and arranged in parallel as longitude silk threads and a group of mixed silk threads with the silk diameter of 0.20mm and arranged in parallel as latitude silk threads, the mixed silk threads comprise polylactic acid silk threads and polylactic acid fiber threads which are alternately arranged and arranged in parallel, the polylactic acid silk threads are 18 and the polylactic acid fiber threads are 36 strands, and the plugging frame is formed by one-pressing one-up and one-down staggered weaving. In the mixed silk threads, the specification of each polylactic acid fiber thread is 600D/144F, and the silk diameter of the polylactic acid silk thread is 0.4mm. The plugging frame comprises a plurality of fasteners for fixing the crossing points of the plugging frame, and the material of the fasteners is polylactic acid fiber thread. The sealing frame comprises a first ridge part, a second ridge part and a waist part, wherein a plurality of fasteners are arranged on the first ridge part, the second ridge part and the waist part of the sealing frame, and the fasteners positioned on the waist part are arranged along the circumferential direction of the waist part and positioned on the same plane. The number of intersections secured by the fasteners accounts for 35% of the total number of intersections of the occluding frame.

The polylactic acid silk thread and the polylactic acid fiber thread (600D/144F, fastened by a non-degradable fixing piece) are soaked in PBS buffer solution at 37 ℃ for in-vitro degradation test, the polylactic acid silk thread and the polylactic acid fiber thread are weighed every month, and a trend curve of the mass retention rate changing along with time is drawn, wherein the time periods of degradation peak stages of the polylactic acid silk thread and the polylactic acid fiber thread are different.

The occluding device of example 9 was implanted in an eight horse pig at the ventricular septum location and during implantation, under DSA equipment, the occluding device could be clearly identified. In two follow-up visits of 1 month and 3 months after implantation, no adverse phenomena such as conduction block and the like are found. After being implanted for 1 year, the plugging device and peripheral tissues are analyzed by pathological sections, and obvious inflammation and foreign body reaction do not exist.

Example 10

An occlusion device comprises an occlusion frame, wherein the occlusion frame is formed by weaving a group of 18 iodinated polylactic acid silk threads with the silk diameter of 0.40mm, which are arranged in parallel, as longitude silk threads and a group of 36 polylactic acid fiber threads, which are arranged in parallel, as latitude silk threads in a one-to-one and up-and-down staggered manner. In the iodinated polylactic acid thread, the mass percent of iodine is 15%. The specification of each polylactic acid fiber wire is 50D/18F.

The occluding device of example 10 was implanted in an eight horse pig at the ventricular septum location and during implantation, under DSA equipment, the occluding device could be clearly identified. In two follow-up visits of 1 month and 3 months after implantation, no adverse phenomena such as conduction block and the like are found. After being implanted for 1 year, the plugging device and peripheral tissues are analyzed by pathological sections, and obvious inflammation and foreign body reaction do not exist.

The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.

The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.

Claims

1. An occlusion instrument comprises an occlusion frame, and is characterized in that the occlusion frame comprises a plurality of polymer braided wires and a plurality of strands of polymer fiber wires, the polymer braided wires and the plurality of strands of polymer fiber wires are braided in a mixed manner to form the occlusion frame, wherein each strand of polymer fiber wire comprises a plurality of polymer fiber wires; the polymer braided wire and the multi-strand polymer fiber wire have peak staggering degradation characteristics;

the specification range of each strand of polymer fiber yarn is 50D/72F-100D/72F, and the yarn diameter range of each polymer knitting yarn is 0.1-0.5 mm.

2. The occlusion device of claim 1, wherein the plurality of polymeric braided filaments are arranged in parallel to form a first dimension filament, the plurality of polymeric fiber strands are arranged in parallel to form a second dimension filament, and the first dimension filament and the second dimension filament are interwoven to form the occlusion frame.

3. The occlusion device of claim 1, wherein a portion of the plurality of polymeric braided filaments are arranged in parallel to form a first dimension filament and another portion of the plurality of polymeric braided filaments are arranged in parallel to the plurality of polymeric fiber strands to form a second dimension filament, the first dimension filament and the second dimension filament being interwoven to form the occlusion frame.

4. The occlusion device of claim 3, wherein the polymeric braided filaments of the first dimension filaments have peak-to-peak degradation characteristics with the polymeric braided filaments of the second dimension filaments; and/or the plurality of polymer fiber threads in the second-dimension silk threads have peak-shifting degradation characteristics.

5. The occlusion device of claim 3, wherein a filament diameter of the polymeric braid in the first dimension filaments is different from a filament diameter of the polymeric braid in the second dimension filaments; and/or the second-dimension silk thread comprises a plurality of polymer fiber threads with different specifications.

6. The occlusion device of claim 3, wherein a ratio of the filament diameter of the polymer-woven filaments of the first-dimension filaments to the filament diameter of the polymer-woven filaments of the second-dimension filaments ranges from 1 to 1.

7. The occlusion device of claim 3, wherein a ratio of the number of the polymeric braided filaments in the first dimension filaments to the sum of the number of the polymeric braided filaments and the polymeric fiber filaments in the second dimension filaments ranges from 1 to 1.

8. The occlusion device of claim 1, wherein a material of at least one of the woven polymeric filaments and the fibrous polymeric threads is a polymer visible under a medical imaging device, the polymer visible under the medical imaging device including a degradable polymer and a visible substance grafted to a molecular chain of the degradable polymer.

9. The occlusion device of claim 8, wherein the amount of the visualization substance in the polymer visible with the medical imaging device is in a range of 5% to 25% by weight.